ImmuCell CorpNASDAQ:ICCC
- LAST PRICE4.5500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots4.4500/ 8
- Ask / Lots4.6500/ 1
- Open / Previous Close0.0000 / 4.5500
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ICCC |
|---|---|---|
| 09:55 ET | 566 | 4.4601 |
| 10:31 ET | 100 | 4.63 |
| 10:58 ET | 300 | 4.555 |
| 11:56 ET | 4500 | 4.56 |
| 11:57 ET | 2000 | 4.55 |
| 12:01 ET | 900 | 4.55 |
| 12:06 ET | 506 | 4.55 |
| 02:07 ET | 3147 | 4.55 |
Nov 13, 2023
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2023, from 4:05PM ET on Monday Nov 13, 2023 by Dow Jones
4:05PM ET on Monday Nov 13, 2023 by Dow Jones*DJ Immucell 3Q Loss $940,000 >ICCC, from 4:05PM ET on Monday Nov 13, 2023 by Dow Jones
4:05PM ET on Monday Nov 13, 2023 by Dow Jones
Nov 7, 2023
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2023, from 12:15PM ET on Tuesday Nov 07, 2023 by Dow Jones
12:15PM ET on Tuesday Nov 07, 2023 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ImmuCell Corp | 35.3M | -5.6x | --- |
Celularity Inc | 40.5M | -0.4x | --- |
LAVA Therapeutics NV | 40.2M | -0.8x | --- |
Molecular Templates Inc | 26.9M | -0.7x | --- |
DURECT Corp | 19.7M | -0.4x | --- |
Avalo Therapeutics Inc | 12.4M | 0.0x | --- |
Company Information
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture and sale of products that improve the health and productivity of dairy and beef cattle. It manufactures and markets the First Defense product line, providing Immediate Immunity for the prevention of scours in newborn dairy and beef calves. It expanded this line into four different products with formulations targeting E. coli, coronavirus and rotavirus pathogens. Its Tri-Shield First Defense product line extension is calf-level, passive antibody product providing immediate immunity against E. coli, coronavirus and rotavirus. This product line provides Immediate Immunity to newborn calves. The Company is engaged in the development of Re-Tain, a Nisin treatment for subclinical mastitis in lactating dairy cows. The Company’s products reduce the use of traditional antibiotics in food producing animals.
Contact Information
- Headquarters
- 56 Evergreen DrivePORTLAND, ME, United States 04103
- Phone
- 207-878-2770
- Fax
- 302-655-5049
Executives
- Independent Non-Executive Chairman of the Board
- David Tomsche
- President, Chief Executive Officer, Treasurer, Secretary, Director
- Michael Brigham
- Vice President - Sales and Marketing, Director
- Bobbi Brockmann
- Vice President - Manufacturing Operations
- Elizabeth Williams
- Independent Director
- Gloria Basse
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $35.3M |
|---|---|
Revenue (TTM) | $16.3M |
Shares Outstanding | 7.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.60 |
EPS | $-0.81 |
Book Value | $3.92 |
P/E Ratio | -5.6x |
Price/Sales (TTM) | 2.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -39.16% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
